(S)-1-(2-Chloro-6-fluorophenyl)ethanamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-1-(2-Chloro-6-fluorophenyl)ethanamine
• 英文别名: (1S)-1-(2-chloro-6-fluorophenyl)ethanamine
• 化学式: C₈H₉ClFN
• 分子量: 173.618
• InChiKey: WLQXZWHHERXWHA-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-1-(2-Chloro-6-fluorophenyl)ethanamine 、 5-cyano-1-methyl-1H-pyrrole-2-carboxylic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 (S)-N-(1-(2-chloro-6-fluorophenyl)ethyl)-5-cyano-1-methyl-1H-pyrrole-2-carboxamide
  参考文献：
  名称：

  Structure–activity relationship and liver microsome stability studies of pyrrole necroptosis inhibitors

  摘要：

  Necroptosis is a regulated caspase-independent cell death pathway resulting in morphology reminiscent of passive nonregulated necrosis. Several diverse structure classes of necroptosis inhibitors have been reported to date, including a series of [1,2,3] thiadiazole benzylamide derivatives. However, initial evaluation of mouse liver microsome stability indicated that this series of compounds was rapidly degraded. A structure-activity relationship (SAR) study of the [1,2,3] thiadiazole benzylamide series revealed that increased mouse liver microsome stability and increased necroptosis inhibitory activity could be accomplished by replacement of the 4-cyclopropyl-[1,2,3] thiadiazole with a 5-cyano-1-methylpyrrole. In addition, the SAR and the cellular activity profiles, utilizing different cell types and necroptosis-inducing stimuli, of representative [1,2,3] thiadiazole and pyrrole derivatives were very similar suggesting that the two compound series inhibit necroptosis in the same manner. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.04.048

文献信息

• BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
  申请人：Xenon Pharmaceuticals Inc.

  公开号：US20180162868A1

  公开（公告）日：2018-06-14

  This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

  这项发明涉及苯磺酰胺化合物，作为其立体异构体、对映异构体、互变异构体或它们的混合物；或其药学上可接受的盐、溶剂合物或前药，用于治疗与电压门控钠通道相关的疾病或症状，如癫痫和/或癫痫发作障碍。
• [EN] HYBRID NECROPTOSIS INHIBITORS<br/>[FR] INHIBITEURS HYBRIDES DE LA NÉCROPTOSE
  申请人：HARVARD COLLEGE

  公开号：WO2014145022A1

  公开（公告）日：2014-09-18

  The present invention relates to heterocyclic compounds (e.g., compounds described by Formula (I)) and pharmaceutically acceptable salts thereof. The invention also features pharmaceutical compositions that include these compounds and their use in therapy for treating conditions in which necroptosis is likely to play a substantial role. The heterocyclic compounds described herein can also achieve improved activity and selectivity towards RIP1 and/or RIP3.

  本发明涉及杂环化合物（例如，由式（I）描述的化合物）及其药学上可接受的盐。该发明还涉及包括这些化合物的药物组合物，以及它们在治疗可能出现大量坏死相关凋亡的疾病中的用途。本文描述的杂环化合物还可以实现对RIP1和/或RIP3的改进活性和选择性。
• [EN] AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIDAZIN-3(2H)-ONE FUSIONNÉS PAR UN AZOLE
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2021055326A1

  公开（公告）日：2021-03-25

  Disclosed are compounds of Formula (1) and pharmaceutically acceptable salts thereof, wherein α, β, n, R4, R5, R6, R8, R9, R10, R11, X1, X2, X3 and X7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions comprising them, and to their use for treating diseases, disorders, and conditions associated with GPR139.

  揭示了Formula（1）的化合物及其药用可接受的盐，其中α、β、n、R4、R5、R6、R8、R9、R10、R11、X1、X2、X3和X7在规范中有定义。本公开还涉及制备Formula（1）化合物的材料和方法，包括含有它们的药物组合物，以及它们用于治疗与GPR139相关的疾病、紊乱和症状的用途。
• [EN] PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS<br/>[FR] PRÉPARATION DE DÉRIVÉS DE COMPOSÉS 1,2-DIAMINOHÉTÉROCYCLIQUES SUBSTITUÉS ET LEUR UTILISATION EN TANT QU'AGENTS PHARMACEUTIQUES
  申请人：AVELOS THERAPEUTICS INC

  公开号：WO2022260441A1

  公开（公告）日：2022-12-15

  This invention relates to compounds which are microtubule associated serine/threonine-like kinase (MASTL) inhibitors and the use of the compounds in the treatment of diseases and medical conditions mediated by MASTL, for example in the treatment of cancer and other target related diseases.

  本发明涉及一种微管相关丝氨酸/苏氨酸样激酶（MASTL）抑制剂化合物及其在治疗由MASTL介导的疾病和医学状况中的应用，例如在治疗癌症和其他相关疾病中的应用。
• HETEROCYCLIC INHIBITORS OF NECROPTOSIS
  申请人：President and Fellows of Harvard College

  公开号：EP3034494A1

  公开（公告）日：2016-06-22

  The invention features a series of heterocyclic derivatives that inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. The heterocyclic compounds of the invention are described by Formulas (I) and (Ia)-(Ie) and are shown to inhibit TNF-α induced necroptosis in FADD-deficient variant of human Jurkat T cells. The invention further features pharmaceutical compositions featuring the compounds of the invention. The compounds and compositions of the invention may also be used to treat disorders where necroptosis is likely to play a substantial role.

  本发明具有一系列抑制肿瘤坏死因子α（TNF-α）诱导坏死的杂环衍生物。本发明的杂环化合物由式(I)和(Ia)-(Ie)描述，并证明可抑制FADD缺陷变体人Jurkat T细胞中TNF-α诱导的坏死。本发明还具有以本发明化合物为特征的药物组合物。本发明的化合物和组合物还可用于治疗坏死可能起重要作用的疾病。